Spruce Biosciences Inc (NAS:SPRB)
$ 0.4037 0.0082 (2.07%) Market Cap: 16.34 Mil Enterprise Value: -40.49 Mil PE Ratio: 0 PB Ratio: 0.32 GF Score: 32/100

Spruce Biosciences Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 15, 2023 / 07:20PM GMT
Release Date Price: $2.73 (+1.11%)
Joseph Schwartz
SVB Securities - Moderator

Hello. Welcome to this presentation with Spruce Biosciences. We're pleased to have Javier Szwarcberg with us today to walk us through the story, provide an update, and then we'll have some Q&A at the end. Thanks so much for being with us, Javier.

Javier Szwarcberg
Spruce Biosciences, Inc. - CEO

Thank you so much, Joe. Much appreciated. So let me start with my presentation here. Through the course of my presentation, I'll be making some forward-looking statements. So I urge you to review prior releases, prior filings that we've made along the way.

So to start, CAH is a fairly large disease, is a $3 billion market opportunity for us. It has low competitive intensity, and a disease that hasn't seen a lot of new therapeutic options in 50 years. With the advent of steroids in the late 50s, early 60s, initially, there were -- frankly, quite transforming, right?

But patients need to take steroids in the context of supply and what's missing, what the body can't make. But in the context of CAH, they

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot